Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences
Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies in patients with locally advanced or metastatic platinum-resistant urothelial carcinoma. To compare the real-life experience and data of clinical trials on ATZ treatment in metastatic urothelial carcinom...
Gespeichert in:
| Veröffentlicht in: | European urology focus 2021-09, Vol.7 (5), p.1061-1066 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1066 |
|---|---|
| container_issue | 5 |
| container_start_page | 1061 |
| container_title | European urology focus |
| container_volume | 7 |
| creator | Tural, Deniz Ölmez, Ömer Fatih Sümbül, Ahmet Taner Artaç, Mehmet Özhan, Nail Akar, Emre Çakar, Burcu Köstek, Osman Ekenel, Meltem Erman, Mustafa Coşkun, Hasan Şenol Selçukbiricik, Fatih Keskin, Özge Türköz, Fatma Paksoy Oruç, Kerem Bayram, Selami Yılmaz, Uğur Bilgetekin, İrem Yıldız, Birol Şendur, Mehmet Ali Nahit Paksoy, Nail Dirican, Ahmet Erdem, Dilek Selam, Meltem Tanrıverdi, Özgür Paydaş, Semra Urakçı, Zuhat Atağ, Elif Güncan, Sabri Ürün, Yüksel Alkan, Ali Kaya, Ali Osman Özyükseler, Deniz Tataroğlu Taşkaynatan, Halil Yıldırım, Mustafa Sönmez, Müge Başoğlu, Tuğba Gündüz, Şeyda Kılıçkap, Saadettin |
| description | Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies in patients with locally advanced or metastatic platinum-resistant urothelial carcinoma.
To compare the real-life experience and data of clinical trials on ATZ treatment in metastatic urothelial carcinoma.
Patients with urothelial cancer treated with ATZ after progression on first-line chemotherapy from an expanded access program were retrospectively studied. Data of patients were obtained from their files and hospital records. Safety was evaluated for patients treated with at least one cycle of ATZ.
The primary endpoint was objective response rate (ORR). The secondary endpoints are overall survival (OS), progression-free survival (PFS), duration of response, and safety profile of patients. Kaplan-Meier methods were used to calculate median follow-up and estimate PFS and OS.
Data of 115 enrolled patients were analyzed. Most of the patients (92.3%, n = 106) had received chemotherapy regimen only once prior to ATZ. The median follow-up duration was 23.5 mo. The complete response rate, partial response rate, and ORR were 8.7% (n = 10), 20.0% (n = 23), and 28.7% (n = 33), respectively. The median duration of response was 20.4 mo (95% confidence interval [CI], 6.47–28.8). Of the 33 patients who responded to treatment, 60% (n = 20) had an ongoing response at the time of the analysis. PFS and OS with ATZ were 3.8 mo (95% CI, 2.25–5.49) and 9.8 mo (95% CI, 6.7–12.9), respectively. All-cause and any-grade adverse events were observed in 113 (98%) patients. Of the patients, 64% experienced a treatment-related adverse event of any grade and 24 (21.2%) had a grade 3–4 treatment-related adverse event. Limitations of the study included its retrospective design, and determination of treatment response based on clinical notes and local radiographic studies.
In these real-life data, ATZ was effective and well tolerated in patients with metastatic urothelial carcinoma who have progressed with platinum-based first-line chemotherapy. ATZ is an effective and tolerable treatment for patients with locally advanced or metastatic platinum-resistant urothelial carcinoma in our study, similar to previously reported trials.
Atezolizumab is effective and well-tolerated in patients with metastatic urothelial cancer who progressed with first-line chemotherapy, consistent with the outcomes of the previous clinical trials in this setting.
Atezolizumab is an effective and tolerable treatment op |
| doi_str_mv | 10.1016/j.euf.2020.09.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2448413188</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2405456920302698</els_id><sourcerecordid>2448413188</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-c72b8599ddd7d2152b7ff2ccb18d54327c74c5d004dc9aa465189b082b8cd2423</originalsourceid><addsrcrecordid>eNp9kc9u1DAQxi0EolXpA3BBPnJJ6n_ZOHBarVqK1KoVouJoOfaE9cqJF9tpad-ib4y3WypOnGY0-n3faOZD6D0lNSV0cbKpYR5qRhipSVcTSl6hQyZIU4lm0b3-pz9AxyltCCG0ES2X_C064JwQ2cruED0uMzwE7x7mUffYTfhaZwdTTvjO5TW-hKxTLiODb2LIa_BOe7zS0bgpjBr_WAd8rm8BX8fwM0JKYPFyyBDxmYspV95NgFdrGHfaqLf3n_A3SLMv_mEorfYFGQCf_t5CLHsNpHfozaB9guPneoRuzk6_r86ri6svX1fLi8rwhufKtKyXTddZa1vLaMP6dhiYMT2VthGctaYVprGECGs6rcWiobLriSwqY5lg_Ah93PtuY_g1Q8pqdMmA93qCMCfFhJCCciplQekeNTGkFGFQ2-hGHe8VJWoXhtqoEobahaFIp0oYRfPh2X7uR7Avir-vL8DnPQDlyFsHUSXz9AHrIpisbHD_sf8DOa2cLQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2448413188</pqid></control><display><type>article</type><title>Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Tural, Deniz ; Ölmez, Ömer Fatih ; Sümbül, Ahmet Taner ; Artaç, Mehmet ; Özhan, Nail ; Akar, Emre ; Çakar, Burcu ; Köstek, Osman ; Ekenel, Meltem ; Erman, Mustafa ; Coşkun, Hasan Şenol ; Selçukbiricik, Fatih ; Keskin, Özge ; Türköz, Fatma Paksoy ; Oruç, Kerem ; Bayram, Selami ; Yılmaz, Uğur ; Bilgetekin, İrem ; Yıldız, Birol ; Şendur, Mehmet Ali Nahit ; Paksoy, Nail ; Dirican, Ahmet ; Erdem, Dilek ; Selam, Meltem ; Tanrıverdi, Özgür ; Paydaş, Semra ; Urakçı, Zuhat ; Atağ, Elif ; Güncan, Sabri ; Ürün, Yüksel ; Alkan, Ali ; Kaya, Ali Osman ; Özyükseler, Deniz Tataroğlu ; Taşkaynatan, Halil ; Yıldırım, Mustafa ; Sönmez, Müge ; Başoğlu, Tuğba ; Gündüz, Şeyda ; Kılıçkap, Saadettin</creator><creatorcontrib>Tural, Deniz ; Ölmez, Ömer Fatih ; Sümbül, Ahmet Taner ; Artaç, Mehmet ; Özhan, Nail ; Akar, Emre ; Çakar, Burcu ; Köstek, Osman ; Ekenel, Meltem ; Erman, Mustafa ; Coşkun, Hasan Şenol ; Selçukbiricik, Fatih ; Keskin, Özge ; Türköz, Fatma Paksoy ; Oruç, Kerem ; Bayram, Selami ; Yılmaz, Uğur ; Bilgetekin, İrem ; Yıldız, Birol ; Şendur, Mehmet Ali Nahit ; Paksoy, Nail ; Dirican, Ahmet ; Erdem, Dilek ; Selam, Meltem ; Tanrıverdi, Özgür ; Paydaş, Semra ; Urakçı, Zuhat ; Atağ, Elif ; Güncan, Sabri ; Ürün, Yüksel ; Alkan, Ali ; Kaya, Ali Osman ; Özyükseler, Deniz Tataroğlu ; Taşkaynatan, Halil ; Yıldırım, Mustafa ; Sönmez, Müge ; Başoğlu, Tuğba ; Gündüz, Şeyda ; Kılıçkap, Saadettin</creatorcontrib><description>Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies in patients with locally advanced or metastatic platinum-resistant urothelial carcinoma.
To compare the real-life experience and data of clinical trials on ATZ treatment in metastatic urothelial carcinoma.
Patients with urothelial cancer treated with ATZ after progression on first-line chemotherapy from an expanded access program were retrospectively studied. Data of patients were obtained from their files and hospital records. Safety was evaluated for patients treated with at least one cycle of ATZ.
The primary endpoint was objective response rate (ORR). The secondary endpoints are overall survival (OS), progression-free survival (PFS), duration of response, and safety profile of patients. Kaplan-Meier methods were used to calculate median follow-up and estimate PFS and OS.
Data of 115 enrolled patients were analyzed. Most of the patients (92.3%, n = 106) had received chemotherapy regimen only once prior to ATZ. The median follow-up duration was 23.5 mo. The complete response rate, partial response rate, and ORR were 8.7% (n = 10), 20.0% (n = 23), and 28.7% (n = 33), respectively. The median duration of response was 20.4 mo (95% confidence interval [CI], 6.47–28.8). Of the 33 patients who responded to treatment, 60% (n = 20) had an ongoing response at the time of the analysis. PFS and OS with ATZ were 3.8 mo (95% CI, 2.25–5.49) and 9.8 mo (95% CI, 6.7–12.9), respectively. All-cause and any-grade adverse events were observed in 113 (98%) patients. Of the patients, 64% experienced a treatment-related adverse event of any grade and 24 (21.2%) had a grade 3–4 treatment-related adverse event. Limitations of the study included its retrospective design, and determination of treatment response based on clinical notes and local radiographic studies.
In these real-life data, ATZ was effective and well tolerated in patients with metastatic urothelial carcinoma who have progressed with platinum-based first-line chemotherapy. ATZ is an effective and tolerable treatment for patients with locally advanced or metastatic platinum-resistant urothelial carcinoma in our study, similar to previously reported trials.
Atezolizumab is effective and well-tolerated in patients with metastatic urothelial cancer who progressed with first-line chemotherapy, consistent with the outcomes of the previous clinical trials in this setting.
Atezolizumab is an effective and tolerable treatment option for patients with urothelial cancer after progression by the chemotherapy. Clinical activity and safety of atezolizumab treatment in real-life patients were consistent with the outcomes of the previous clinical trials in this setting</description><identifier>ISSN: 2405-4569</identifier><identifier>EISSN: 2405-4569</identifier><identifier>DOI: 10.1016/j.euf.2020.09.010</identifier><identifier>PMID: 33008789</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Antibodies, Monoclonal, Humanized ; Atezolizumab ; Bladder cancer ; Carcinoma, Transitional Cell - pathology ; Humans ; Immunotherapy ; Retrospective Studies ; Urinary Bladder Neoplasms - drug therapy ; Urologic Neoplasms - pathology ; Urothelial carcinoma</subject><ispartof>European urology focus, 2021-09, Vol.7 (5), p.1061-1066</ispartof><rights>2020 European Association of Urology</rights><rights>Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-c72b8599ddd7d2152b7ff2ccb18d54327c74c5d004dc9aa465189b082b8cd2423</citedby><cites>FETCH-LOGICAL-c353t-c72b8599ddd7d2152b7ff2ccb18d54327c74c5d004dc9aa465189b082b8cd2423</cites><orcidid>0000-0003-2144-6469</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33008789$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tural, Deniz</creatorcontrib><creatorcontrib>Ölmez, Ömer Fatih</creatorcontrib><creatorcontrib>Sümbül, Ahmet Taner</creatorcontrib><creatorcontrib>Artaç, Mehmet</creatorcontrib><creatorcontrib>Özhan, Nail</creatorcontrib><creatorcontrib>Akar, Emre</creatorcontrib><creatorcontrib>Çakar, Burcu</creatorcontrib><creatorcontrib>Köstek, Osman</creatorcontrib><creatorcontrib>Ekenel, Meltem</creatorcontrib><creatorcontrib>Erman, Mustafa</creatorcontrib><creatorcontrib>Coşkun, Hasan Şenol</creatorcontrib><creatorcontrib>Selçukbiricik, Fatih</creatorcontrib><creatorcontrib>Keskin, Özge</creatorcontrib><creatorcontrib>Türköz, Fatma Paksoy</creatorcontrib><creatorcontrib>Oruç, Kerem</creatorcontrib><creatorcontrib>Bayram, Selami</creatorcontrib><creatorcontrib>Yılmaz, Uğur</creatorcontrib><creatorcontrib>Bilgetekin, İrem</creatorcontrib><creatorcontrib>Yıldız, Birol</creatorcontrib><creatorcontrib>Şendur, Mehmet Ali Nahit</creatorcontrib><creatorcontrib>Paksoy, Nail</creatorcontrib><creatorcontrib>Dirican, Ahmet</creatorcontrib><creatorcontrib>Erdem, Dilek</creatorcontrib><creatorcontrib>Selam, Meltem</creatorcontrib><creatorcontrib>Tanrıverdi, Özgür</creatorcontrib><creatorcontrib>Paydaş, Semra</creatorcontrib><creatorcontrib>Urakçı, Zuhat</creatorcontrib><creatorcontrib>Atağ, Elif</creatorcontrib><creatorcontrib>Güncan, Sabri</creatorcontrib><creatorcontrib>Ürün, Yüksel</creatorcontrib><creatorcontrib>Alkan, Ali</creatorcontrib><creatorcontrib>Kaya, Ali Osman</creatorcontrib><creatorcontrib>Özyükseler, Deniz Tataroğlu</creatorcontrib><creatorcontrib>Taşkaynatan, Halil</creatorcontrib><creatorcontrib>Yıldırım, Mustafa</creatorcontrib><creatorcontrib>Sönmez, Müge</creatorcontrib><creatorcontrib>Başoğlu, Tuğba</creatorcontrib><creatorcontrib>Gündüz, Şeyda</creatorcontrib><creatorcontrib>Kılıçkap, Saadettin</creatorcontrib><title>Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences</title><title>European urology focus</title><addtitle>Eur Urol Focus</addtitle><description>Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies in patients with locally advanced or metastatic platinum-resistant urothelial carcinoma.
To compare the real-life experience and data of clinical trials on ATZ treatment in metastatic urothelial carcinoma.
Patients with urothelial cancer treated with ATZ after progression on first-line chemotherapy from an expanded access program were retrospectively studied. Data of patients were obtained from their files and hospital records. Safety was evaluated for patients treated with at least one cycle of ATZ.
The primary endpoint was objective response rate (ORR). The secondary endpoints are overall survival (OS), progression-free survival (PFS), duration of response, and safety profile of patients. Kaplan-Meier methods were used to calculate median follow-up and estimate PFS and OS.
Data of 115 enrolled patients were analyzed. Most of the patients (92.3%, n = 106) had received chemotherapy regimen only once prior to ATZ. The median follow-up duration was 23.5 mo. The complete response rate, partial response rate, and ORR were 8.7% (n = 10), 20.0% (n = 23), and 28.7% (n = 33), respectively. The median duration of response was 20.4 mo (95% confidence interval [CI], 6.47–28.8). Of the 33 patients who responded to treatment, 60% (n = 20) had an ongoing response at the time of the analysis. PFS and OS with ATZ were 3.8 mo (95% CI, 2.25–5.49) and 9.8 mo (95% CI, 6.7–12.9), respectively. All-cause and any-grade adverse events were observed in 113 (98%) patients. Of the patients, 64% experienced a treatment-related adverse event of any grade and 24 (21.2%) had a grade 3–4 treatment-related adverse event. Limitations of the study included its retrospective design, and determination of treatment response based on clinical notes and local radiographic studies.
In these real-life data, ATZ was effective and well tolerated in patients with metastatic urothelial carcinoma who have progressed with platinum-based first-line chemotherapy. ATZ is an effective and tolerable treatment for patients with locally advanced or metastatic platinum-resistant urothelial carcinoma in our study, similar to previously reported trials.
Atezolizumab is effective and well-tolerated in patients with metastatic urothelial cancer who progressed with first-line chemotherapy, consistent with the outcomes of the previous clinical trials in this setting.
Atezolizumab is an effective and tolerable treatment option for patients with urothelial cancer after progression by the chemotherapy. Clinical activity and safety of atezolizumab treatment in real-life patients were consistent with the outcomes of the previous clinical trials in this setting</description><subject>Antibodies, Monoclonal, Humanized</subject><subject>Atezolizumab</subject><subject>Bladder cancer</subject><subject>Carcinoma, Transitional Cell - pathology</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Retrospective Studies</subject><subject>Urinary Bladder Neoplasms - drug therapy</subject><subject>Urologic Neoplasms - pathology</subject><subject>Urothelial carcinoma</subject><issn>2405-4569</issn><issn>2405-4569</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc9u1DAQxi0EolXpA3BBPnJJ6n_ZOHBarVqK1KoVouJoOfaE9cqJF9tpad-ib4y3WypOnGY0-n3faOZD6D0lNSV0cbKpYR5qRhipSVcTSl6hQyZIU4lm0b3-pz9AxyltCCG0ES2X_C064JwQ2cruED0uMzwE7x7mUffYTfhaZwdTTvjO5TW-hKxTLiODb2LIa_BOe7zS0bgpjBr_WAd8rm8BX8fwM0JKYPFyyBDxmYspV95NgFdrGHfaqLf3n_A3SLMv_mEorfYFGQCf_t5CLHsNpHfozaB9guPneoRuzk6_r86ri6svX1fLi8rwhufKtKyXTddZa1vLaMP6dhiYMT2VthGctaYVprGECGs6rcWiobLriSwqY5lg_Ah93PtuY_g1Q8pqdMmA93qCMCfFhJCCciplQekeNTGkFGFQ2-hGHe8VJWoXhtqoEobahaFIp0oYRfPh2X7uR7Avir-vL8DnPQDlyFsHUSXz9AHrIpisbHD_sf8DOa2cLQ</recordid><startdate>202109</startdate><enddate>202109</enddate><creator>Tural, Deniz</creator><creator>Ölmez, Ömer Fatih</creator><creator>Sümbül, Ahmet Taner</creator><creator>Artaç, Mehmet</creator><creator>Özhan, Nail</creator><creator>Akar, Emre</creator><creator>Çakar, Burcu</creator><creator>Köstek, Osman</creator><creator>Ekenel, Meltem</creator><creator>Erman, Mustafa</creator><creator>Coşkun, Hasan Şenol</creator><creator>Selçukbiricik, Fatih</creator><creator>Keskin, Özge</creator><creator>Türköz, Fatma Paksoy</creator><creator>Oruç, Kerem</creator><creator>Bayram, Selami</creator><creator>Yılmaz, Uğur</creator><creator>Bilgetekin, İrem</creator><creator>Yıldız, Birol</creator><creator>Şendur, Mehmet Ali Nahit</creator><creator>Paksoy, Nail</creator><creator>Dirican, Ahmet</creator><creator>Erdem, Dilek</creator><creator>Selam, Meltem</creator><creator>Tanrıverdi, Özgür</creator><creator>Paydaş, Semra</creator><creator>Urakçı, Zuhat</creator><creator>Atağ, Elif</creator><creator>Güncan, Sabri</creator><creator>Ürün, Yüksel</creator><creator>Alkan, Ali</creator><creator>Kaya, Ali Osman</creator><creator>Özyükseler, Deniz Tataroğlu</creator><creator>Taşkaynatan, Halil</creator><creator>Yıldırım, Mustafa</creator><creator>Sönmez, Müge</creator><creator>Başoğlu, Tuğba</creator><creator>Gündüz, Şeyda</creator><creator>Kılıçkap, Saadettin</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2144-6469</orcidid></search><sort><creationdate>202109</creationdate><title>Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences</title><author>Tural, Deniz ; Ölmez, Ömer Fatih ; Sümbül, Ahmet Taner ; Artaç, Mehmet ; Özhan, Nail ; Akar, Emre ; Çakar, Burcu ; Köstek, Osman ; Ekenel, Meltem ; Erman, Mustafa ; Coşkun, Hasan Şenol ; Selçukbiricik, Fatih ; Keskin, Özge ; Türköz, Fatma Paksoy ; Oruç, Kerem ; Bayram, Selami ; Yılmaz, Uğur ; Bilgetekin, İrem ; Yıldız, Birol ; Şendur, Mehmet Ali Nahit ; Paksoy, Nail ; Dirican, Ahmet ; Erdem, Dilek ; Selam, Meltem ; Tanrıverdi, Özgür ; Paydaş, Semra ; Urakçı, Zuhat ; Atağ, Elif ; Güncan, Sabri ; Ürün, Yüksel ; Alkan, Ali ; Kaya, Ali Osman ; Özyükseler, Deniz Tataroğlu ; Taşkaynatan, Halil ; Yıldırım, Mustafa ; Sönmez, Müge ; Başoğlu, Tuğba ; Gündüz, Şeyda ; Kılıçkap, Saadettin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-c72b8599ddd7d2152b7ff2ccb18d54327c74c5d004dc9aa465189b082b8cd2423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibodies, Monoclonal, Humanized</topic><topic>Atezolizumab</topic><topic>Bladder cancer</topic><topic>Carcinoma, Transitional Cell - pathology</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Retrospective Studies</topic><topic>Urinary Bladder Neoplasms - drug therapy</topic><topic>Urologic Neoplasms - pathology</topic><topic>Urothelial carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tural, Deniz</creatorcontrib><creatorcontrib>Ölmez, Ömer Fatih</creatorcontrib><creatorcontrib>Sümbül, Ahmet Taner</creatorcontrib><creatorcontrib>Artaç, Mehmet</creatorcontrib><creatorcontrib>Özhan, Nail</creatorcontrib><creatorcontrib>Akar, Emre</creatorcontrib><creatorcontrib>Çakar, Burcu</creatorcontrib><creatorcontrib>Köstek, Osman</creatorcontrib><creatorcontrib>Ekenel, Meltem</creatorcontrib><creatorcontrib>Erman, Mustafa</creatorcontrib><creatorcontrib>Coşkun, Hasan Şenol</creatorcontrib><creatorcontrib>Selçukbiricik, Fatih</creatorcontrib><creatorcontrib>Keskin, Özge</creatorcontrib><creatorcontrib>Türköz, Fatma Paksoy</creatorcontrib><creatorcontrib>Oruç, Kerem</creatorcontrib><creatorcontrib>Bayram, Selami</creatorcontrib><creatorcontrib>Yılmaz, Uğur</creatorcontrib><creatorcontrib>Bilgetekin, İrem</creatorcontrib><creatorcontrib>Yıldız, Birol</creatorcontrib><creatorcontrib>Şendur, Mehmet Ali Nahit</creatorcontrib><creatorcontrib>Paksoy, Nail</creatorcontrib><creatorcontrib>Dirican, Ahmet</creatorcontrib><creatorcontrib>Erdem, Dilek</creatorcontrib><creatorcontrib>Selam, Meltem</creatorcontrib><creatorcontrib>Tanrıverdi, Özgür</creatorcontrib><creatorcontrib>Paydaş, Semra</creatorcontrib><creatorcontrib>Urakçı, Zuhat</creatorcontrib><creatorcontrib>Atağ, Elif</creatorcontrib><creatorcontrib>Güncan, Sabri</creatorcontrib><creatorcontrib>Ürün, Yüksel</creatorcontrib><creatorcontrib>Alkan, Ali</creatorcontrib><creatorcontrib>Kaya, Ali Osman</creatorcontrib><creatorcontrib>Özyükseler, Deniz Tataroğlu</creatorcontrib><creatorcontrib>Taşkaynatan, Halil</creatorcontrib><creatorcontrib>Yıldırım, Mustafa</creatorcontrib><creatorcontrib>Sönmez, Müge</creatorcontrib><creatorcontrib>Başoğlu, Tuğba</creatorcontrib><creatorcontrib>Gündüz, Şeyda</creatorcontrib><creatorcontrib>Kılıçkap, Saadettin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology focus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tural, Deniz</au><au>Ölmez, Ömer Fatih</au><au>Sümbül, Ahmet Taner</au><au>Artaç, Mehmet</au><au>Özhan, Nail</au><au>Akar, Emre</au><au>Çakar, Burcu</au><au>Köstek, Osman</au><au>Ekenel, Meltem</au><au>Erman, Mustafa</au><au>Coşkun, Hasan Şenol</au><au>Selçukbiricik, Fatih</au><au>Keskin, Özge</au><au>Türköz, Fatma Paksoy</au><au>Oruç, Kerem</au><au>Bayram, Selami</au><au>Yılmaz, Uğur</au><au>Bilgetekin, İrem</au><au>Yıldız, Birol</au><au>Şendur, Mehmet Ali Nahit</au><au>Paksoy, Nail</au><au>Dirican, Ahmet</au><au>Erdem, Dilek</au><au>Selam, Meltem</au><au>Tanrıverdi, Özgür</au><au>Paydaş, Semra</au><au>Urakçı, Zuhat</au><au>Atağ, Elif</au><au>Güncan, Sabri</au><au>Ürün, Yüksel</au><au>Alkan, Ali</au><au>Kaya, Ali Osman</au><au>Özyükseler, Deniz Tataroğlu</au><au>Taşkaynatan, Halil</au><au>Yıldırım, Mustafa</au><au>Sönmez, Müge</au><au>Başoğlu, Tuğba</au><au>Gündüz, Şeyda</au><au>Kılıçkap, Saadettin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences</atitle><jtitle>European urology focus</jtitle><addtitle>Eur Urol Focus</addtitle><date>2021-09</date><risdate>2021</risdate><volume>7</volume><issue>5</issue><spage>1061</spage><epage>1066</epage><pages>1061-1066</pages><issn>2405-4569</issn><eissn>2405-4569</eissn><abstract>Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies in patients with locally advanced or metastatic platinum-resistant urothelial carcinoma.
To compare the real-life experience and data of clinical trials on ATZ treatment in metastatic urothelial carcinoma.
Patients with urothelial cancer treated with ATZ after progression on first-line chemotherapy from an expanded access program were retrospectively studied. Data of patients were obtained from their files and hospital records. Safety was evaluated for patients treated with at least one cycle of ATZ.
The primary endpoint was objective response rate (ORR). The secondary endpoints are overall survival (OS), progression-free survival (PFS), duration of response, and safety profile of patients. Kaplan-Meier methods were used to calculate median follow-up and estimate PFS and OS.
Data of 115 enrolled patients were analyzed. Most of the patients (92.3%, n = 106) had received chemotherapy regimen only once prior to ATZ. The median follow-up duration was 23.5 mo. The complete response rate, partial response rate, and ORR were 8.7% (n = 10), 20.0% (n = 23), and 28.7% (n = 33), respectively. The median duration of response was 20.4 mo (95% confidence interval [CI], 6.47–28.8). Of the 33 patients who responded to treatment, 60% (n = 20) had an ongoing response at the time of the analysis. PFS and OS with ATZ were 3.8 mo (95% CI, 2.25–5.49) and 9.8 mo (95% CI, 6.7–12.9), respectively. All-cause and any-grade adverse events were observed in 113 (98%) patients. Of the patients, 64% experienced a treatment-related adverse event of any grade and 24 (21.2%) had a grade 3–4 treatment-related adverse event. Limitations of the study included its retrospective design, and determination of treatment response based on clinical notes and local radiographic studies.
In these real-life data, ATZ was effective and well tolerated in patients with metastatic urothelial carcinoma who have progressed with platinum-based first-line chemotherapy. ATZ is an effective and tolerable treatment for patients with locally advanced or metastatic platinum-resistant urothelial carcinoma in our study, similar to previously reported trials.
Atezolizumab is effective and well-tolerated in patients with metastatic urothelial cancer who progressed with first-line chemotherapy, consistent with the outcomes of the previous clinical trials in this setting.
Atezolizumab is an effective and tolerable treatment option for patients with urothelial cancer after progression by the chemotherapy. Clinical activity and safety of atezolizumab treatment in real-life patients were consistent with the outcomes of the previous clinical trials in this setting</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>33008789</pmid><doi>10.1016/j.euf.2020.09.010</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-2144-6469</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2405-4569 |
| ispartof | European urology focus, 2021-09, Vol.7 (5), p.1061-1066 |
| issn | 2405-4569 2405-4569 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2448413188 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Antibodies, Monoclonal, Humanized Atezolizumab Bladder cancer Carcinoma, Transitional Cell - pathology Humans Immunotherapy Retrospective Studies Urinary Bladder Neoplasms - drug therapy Urologic Neoplasms - pathology Urothelial carcinoma |
| title | Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T02%3A37%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atezolizumab%20in%20Patients%20with%20Metastatic%20Urothelial%20Carcinoma%20Who%20Have%20Progressed%20After%20First-line%20Chemotherapy:%20Results%20of%20Real-life%20Experiences&rft.jtitle=European%20urology%20focus&rft.au=Tural,%20Deniz&rft.date=2021-09&rft.volume=7&rft.issue=5&rft.spage=1061&rft.epage=1066&rft.pages=1061-1066&rft.issn=2405-4569&rft.eissn=2405-4569&rft_id=info:doi/10.1016/j.euf.2020.09.010&rft_dat=%3Cproquest_cross%3E2448413188%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2448413188&rft_id=info:pmid/33008789&rft_els_id=S2405456920302698&rfr_iscdi=true |